Pappas Capital
Pappas Capital is a global venture capital and commercial development firm dedicated to advancing life science discoveries and bringing groundbreaking solutions to market. With over 30 years of experience, the firm has invested in more than 90 companies across the United States, Canada, and Asia, focusing on life sciences, agriculture, and technology. Pappas Capital operates through three main lines of business: Pappas Ventures, Specialized Fund Management, and Translational Medicine, partnering with research universities to accelerate scientific discoveries.
Pappas Capital
What We Do
Creating, guiding, connecting, and funding innovative life science companies from concept to commercialization.
Structuring and managing customized investment vehicles to meet the strategic needs of investors.
Partnering with leading academic institutions to accelerate the development of research discoveries and inventions.
Industry Focus
Portfolio
Developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases.
#Biopharmaceutical
Leader in the development of precision-guided AAV gene medicines based on directed evolution.
#Gene Therapy
Developing therapies that could raise the IQ of people with intellectual disabilities, such as Down Syndrome.
#Biopharmaceutical
Developing a lasting, functional cure for chronic Hepatitis B Virus (HBV) using epigenetic silencing technology.
#Epigenome Editing
Focused on developing small molecule drugs for infectious diseases, including hepatitis C.
#Pharmaceutical
A leader in the development of small molecule compounds targeting P2X3 for the treatment of poorly managed and common neurogenic disorders, such as chronic cough. Announced positive top-line results from its Phase 2b dose escalation clinical trial of AF-219 in chronic cough patients.
#Pharmaceutical